

APC Policy 162

Blueteq Rechargeable

Drugs List

Berkshire West Area Prescribing Committee

Version 1.0

May 2017

Complied on behalf of the Area Prescribing Committee by

David Pollock

Clinical Integration Pharmacist

Amaka Scott

Lead Interface Pharmacist

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 1 of 16	

Table of Contents

Background	3
Purpose	3
How to use this document	3
Blueteq	3
Initiation Forms	4
Continuation Forms.....	4
Funding.....	4
Disease List	5
Dermatology	5
Psoriasis	5
Gastroenterology	5
Crohn’s Disease.....	5
Ulcerative Colitis.....	6
Ophthalmology	6
Branch Retinal Vein Occlusion	6
Central Retinal Vein Occlusion	6
Diabetic Macular Oedema.....	6
Diabetic Macular Oedema.....	7
Wet Age-related Macular Degeneration	7
Rheumatology	7
Ankylosing Spondylitis.....	7
Non-radiographic Axial Spondyloarthritis	8
Osteoporotic fragility fractures in post menopausal women (secondary prevention)	8
Psoriatic Arthritis.....	8
Rheumatoid Arthritis.....	9
Drug List	10
Abatacept (Orencia®)	10
Adalimumab (Humira®).....	10
Aflibercept (Eylea®).....	10
Apremilast (Otezla®)	11
Bevacizumab (Avastin®)	11
Certolizumab (Cimzia®)	11
Dexamethasone Intravitreal Implant (Ozurdex®)	11
Etanercept (Benepali®).....	12
Etanercept (Enbrel®)	12
Fluocinolone acetonide (Iluvien®).....	12
Golimumab (Simponi®)	12
Infliximab (Inflectra®).....	13
Infliximab (Remicade®).....	13
Infliximab (Remsima®).....	13
Ranibizumab (Lucentis®)	14
Rituximab (MabThera®)	14
Rituximab (Truxima®).....	14
Secukinumab (Cosentyx®).....	14
Teriparatide (Forsteo®)	15
Tocilizumab (RoActemra®)	15
Ustekinumab (Stelara®).....	15
Vedolizumab (Entyvio®)	15

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 2 of 16	

Introduction

Background

Rechargeable drugs, often referred to as Payment by Results (PbR) Excluded drugs, are those which are excluded from the national tariff or PbR system. They are typically specialist, and their use is concentrated in a relatively small number of centres rather than evenly across all trusts that carry out activity in the relevant HRGs. These drugs would therefore not be fairly reimbursed if they were funded through the tariff. The direct cost for these drugs are therefore rechargeable back to a relevant commissioner.

Purpose

This document is designed to help Trust clinical and financial teams to identify which rechargeable drugs require an application for funding approval via the online management system, Blueteq.

This document relates only drugs which are rechargeable back to the Berkshire West Clinical Commissioning Groups (BWCC), which comprise of the following CCGs;

- Newbury and District CCG
- North and West Reading CCG
- South Reading CCG
- Wokingham CCG

For rechargeable drugs relating to any other commissioner, please contact them directly for more information.

The drugs and indications listed within this document are **not** an exhaustive list of rechargeable drugs to BW CCG and only relate to those which require Blueteq Applications for funding to be authorized. All other treatments will be funded through the current payments system. Please contact your finance department for more information.

The drugs/treatments listed within this document will be updated no more frequently than every 3 months.

How to use this document

The document is separated in to two sections. The first is a list of diseases, grouped by specialty, which detail the rechargeable drugs available for their treatment. The second section is an alphabetical list of drugs which includes the detail of every indication that requires a Blueteq application, including the type of forms available (see below).

Blueteq

This document is not a guide to access of use of the online Blueteq system. If you require an account, administrative changes or training on the Blueteq system, please contact the appropriate administrator from within your Trust. Blueteq forms require the entry of clinical information relating to each patient, the details of which can be found within each application form. There are two types of application forms that can be completed for each treatment - initiation and continuation forms (see below) accessible via <https://www.blueteq-secure.co.uk/trust>.

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 3 of 16	

Initiation Forms

These are used when a patient is starting on a new treatment. This application is for funding the *initial* treatment period, with further funding request required (via continuation form) for continued use. The period of funding received from an initiation form is shorter than for continuation and is designed to allow sufficient time establish treatment benefit (in line with local/national guidelines) but require a follow up to measure and record this outcome(s).

Please note that some brands of drug will not have an initiation available; it is expected that the cheaper brand (i.e. biosimilar) is always used for initiation.

Continuation Forms

These forms are used for patients who have been started on treatment and have established benefit from the treatment (in line with local/national guidelines) and require ongoing funding. The continuation form will grant funding for a set period (i.e. 12 months) **or** for a set course of treatment (i.e. 6 doses). Funding for further treatment will require the submission of subsequent continuation forms.

Funding

In line with the agreed Service Development and Improvement Plan (SDIP) in place with the Royal Berkshire Hospital Foundation Trust, the CCG have agreed a 2 year roll out plan for Blueteq starting on 1st April 2017. Therefore, all treatments listed in this document will require a Blueteq application to allow the treatment to be recharged to CCG, but this will only be enforced from 1st April 2019. An application form must be received within 2 months of a patient starting on treatment for it to be included within the corresponding Blueteq application.

Failure to complete an appropriate Blueteq application, in line with the criteria set out in this policy, may result in the CCG refusing to cover the cost of treatment.

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 4 of 16	

Disease List

Dermatology

Psoriasis

- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Apremilast (Otezla[®])**
 - Initiation
 - Continuation
- **Etanercept (Benepali[®])**
 - Initiation
 - Continuation
- **Etanercept (Enbrel[®])**
 - Continuation ONLY
- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Secukinumab (Cosentyx[®])**
 - Initiation
 - Continuation
- **Ustekinumab (Stelara[®])**
 - Initiation
 - Continuation

Gastroenterology

Crohn's Disease

- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Vedolizumab (Entyvio[®])**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 5 of 16	

Ulcerative Colitis

- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Golimumab (Simponi[®])**
 - Initiation
 - Continuation
- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Vedolizumab (Entyvio[®])**
 - Initiation
 - Continuation

Ophthalmology

Branch Retinal Vein Occlusion

- **Aflibercept (Eylea[®])**
 - Initiation
 - Continuation
- **Dexamethasone Intravitreal Implant (Ozurdex[®])**
 - Initiation
 - Continuation (repeat treatment)
- **Ranibizumab (Lucentis[®])**
 - Initiation
 - Continuation

Central Retinal Vein Occlusion

- **Aflibercept (Eylea[®])**
 - Initiation
 - Continuation
- **Dexamethasone Intravitreal Implant (Ozurdex[®])**
 - Initiation
 - Continuation (repeat treatment)
- **Ranibizumab (Lucentis[®])**
 - Initiation
 - Continuation

Diabetic Macular Oedema

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 6 of 16	

- **Aflibercept (Eylea[®])**
 - Initiation
 - Continuation
- **Bevacizumab (Avastin[®])**
 - Initiation
 - Continuation
- **Dexamethasone Intravitreal Implant (Ozurdex[®])**
 - Initiation
 - Continuation (repeat treatment)
- **Fluocinolone acetonide (Iluvien[®])**
 - Initiation
 - Continuation
- **Ranibizumab (Lucentis[®])**
 - Initiation
 - Continuation

Diabetic Macular Oedema

- **Bevacizumab (Avastin[®])**
 - Initiation
 - Continuation
- **Dexamethasone Intravitreal Implant (Ozurdex[®])**
 - Initiation
 - Continuation (repeat treatment)

Wet Age-related Macular Degeneration

- **Aflibercept (Eylea[®])**
 - Initiation (switch from Ranibizumab)
 - Continuation
- **Bevacizumab (Avastin[®])**
 - Initiation
 - Continuation
- **Ranibizumab (Lucentis[®])**
 - Initiation
 - Continuation

Rheumatology

Ankylosing Spondylitis

- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Certolizumab (Cimzia[®])**
 - Initiation
 - Continuation
- **Etanercept (Benepali[®])**
 - Initiation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 7 of 16	

- Continuation
- **Etanercept (Enbrel[®])**
 - Continuation ONLY
- **Golimumab (Simponi[®])**
 - Initiation
 - Continuation
- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Secukinumab (Cosentyx[®])**
 - Initiation
 - Continuation

Non-radiographic Axial Spondyloarthritis

- **Certolizumab (Cimzia[®])**
 - Initiation
 - Continuation

Osteoporotic fragility fractures in post menopausal women (secondary prevention)

- **Teriparatide (Forsteo[®])**
 - Initiation ONLY (max 24 months treatment)

Psoriatic Arthritis

- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Apremilast (Otezla[®])**
 - Initiation
 - Continuation
- **Certolizumab (Cimzia[®])**
 - Initiation
 - Continuation
- **Etanercept (Benepali[®])**
 - Initiation
 - Continuation
- **Etanercept (Enbrel[®])**
 - Continuation ONLY
- **Golimumab (Simponi[®])**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 8 of 16	

- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Secukinumab (Cosentyx[®])**
 - Initiation
 - Continuation
- **Ustekinumab (Stelara[®])**
 - Initiation
 - Continuation

Rheumatoid Arthritis

- **Abatacept (Orencia[®])**
 - Initiation
 - Continuation
- **Adalimumab (Humira[®])**
 - Initiation
 - Continuation
- **Certolizumab (Cimzia[®])**
 - Initiation
 - Continuation
- **Etanercept (Benepali[®])**
 - Initiation
 - Continuation
- **Etanercept (Enbrel[®])**
 - Continuation ONLY
- **Golimumab (Simponi[®])**
 - Initiation
 - Continuation
- **Infliximab (Inflectra[®])**
 - Initiation
 - Continuation
- **Infliximab (Remicade[®])**
 - Continuation ONLY
- **Infliximab (Remsima[®])**
 - Initiation
 - Continuation
- **Rituximab (MabThera[®])**
 - Continuation ONLY
- **Rituximab (Truxima[®])**
 - Initiation
 - Continuation
- **Tocilizumab (RoActemra[®])**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 9 of 16	

Drug List

Abatacept (Orencia®)

- **Rheumatoid Arthritis**
 - o Initiation
 - o Continuation

Adalimumab (Humira®)

- **Ankylosing Spondylitis**
 - o Initiation
 - o Continuation
- **Crohn's Disease**
 - o Initiation
 - o Continuation
- **Non-Radiographical Axial Spondyloarthritis**
 - o Initiation
 - o Continuation
- **Psoriatic Arthritis**
 - o Initiation
 - o Continuation
- **Psoriasis**
 - o Initiation
 - o Continuation
- **Rheumatoid Arthritis**
 - o Initiation
 - o Continuation
- **Ulcerative Colitis**
 - o Initiation
 - o Continuation

Aflibercept (Eylea®)

- **Branch Retinal Vein Occlusion**
 - o Initiation
 - o Continuation
- **Central Retinal Vein Occlusion**
 - o Initiation
 - o Continuation
- **Diabetic Macular Oedema**
 - o Initiation
 - o Continuation
- **Wet Age-related Macular Degeneration**
 - o Initiation (switch from Ranibizumab)
 - o Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 10 of 16	

Apremilast (Otezla®)

- **Psoriatic Arthritis**
 - o Initiation
 - o Continuation
- **Psoriasis**
 - o Initiation
 - o Continuation

Bevacizumab (Avastin®)

- **Diabetic Macular Oedema**
 - o Initiation
 - o Continuation
- **Uveitis**
 - o Initiation
 - o Continuation
- **Wet Age-related Macular Degeneration**
 - o Initiation
 - o Continuation

Certolizumab (Cimzia®)

- **Ankylosing Spondylitis**
 - o Initiation
 - o Continuation
- **Non-Radiographical Axial Spondyloarthritis**
 - o Initiation
 - o Continuation
- **Psoriatic Arthritis**
 - o Initiation
 - o Continuation
- **Rheumatoid Arthritis**
 - o Initiation
 - o Continuation

Dexamethasone Intravitreal Implant (Ozurdex®)

- **Branch Retinal Vein Occlusion**
 - o Initiation
 - o Continuation (repeat treatment)
- **Central Retinal Vein Occlusion**
 - o Initiation
 - o Continuation (repeat treatment)
- **Diabetic Macular Oedema**
 - o Initiation
 - o Continuation (repeat treatment)
- **Uveitis**
 - o Initiation
 - o Continuation (repeat treatment)

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 11 of 16	

Etanercept (Benepali®)

- **Ankylosing Spondylitis**
 - Initiation
 - Continuation
- **Non-Radiographical Axial Spondyloarthritis**
 - Initiation
 - Continuation
- **Psoriatic Arthritis**
 - Initiation
 - Continuation
- **Psoriasis**
 - Initiation
 - Continuation
- **Rheumatoid Arthritis**
 - Initiation
 - Continuation

Etanercept (Enbrel®)

- **Ankylosing Spondylitis**
 - Continuation ONLY
- **Non-Radiographical Axial Spondyloarthritis**
 - Continuation ONLY
- **Psoriatic Arthritis**
 - Continuation ONLY
- **Psoriasis**
 - Continuation ONLY
- **Rheumatoid Arthritis**
 - Continuation ONLY

Fluocinolone acetonide (Iluvien®)

- **Diabetic Macular Oedema**
 - Initiation
 - Continuation

Golimumab (Simponi®)

- **Ankylosing Spondylitis**
 - Initiation
 - Continuation
- **Psoriatic Arthritis**
 - Initiation
 - Continuation
- **Rheumatoid Arthritis**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 12 of 16	

- **Ulcerative Colitis**
 - o Initiation
 - o Continuation

Infliximab (Inflectra®)

- **Ankylosing Spondylitis**
 - o Initiation
 - o Continuation
- **Crohn's Disease**
 - o Initiation
 - o Continuation
- **Psoriatic Arthritis**
 - o Initiation
 - o Continuation
- **Psoriasis**
 - o Initiation
 - o Continuation
- **Rheumatoid Arthritis**
 - o Initiation
 - o Continuation
- **Ulcerative Colitis**
 - o Initiation
 - o Continuation

Infliximab (Remicade®)

- **Ankylosing Spondylitis**
 - o Continuation ONLY
- **Crohn's Disease**
 - o Continuation ONLY
- **Psoriatic Arthritis**
 - o Continuation ONLY
- **Psoriasis**
 - o Continuation ONLY
- **Rheumatoid Arthritis**
 - o Continuation ONLY
- **Ulcerative Colitis**
 - o Continuation ONLY

Infliximab (Remsima®)

- **Ankylosing Spondylitis**
 - o Initiation
 - o Continuation
- **Crohn's Disease**
 - o Initiation
 - o Continuation
- **Psoriatic Arthritis**
 - o Initiation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 13 of 16	

- Continuation
- **Psoriasis**
 - Initiation
 - Continuation
- **Rheumatoid Arthritis**
 - Initiation
 - Continuation
- **Ulcerative Colitis**
 - Initiation
 - Continuation

Ranibizumab (Lucentis®)

- **Branch Retinal Vein Occlusion**
 - Initiation
 - Continuation
- **Central Retinal Vein Occlusion**
 - Initiation
 - Continuation
- **Diabetic Macular Oedema**
 - Initiation
 - Continuation
- **Wet Age-related Macular Degeneration**
 - Initiation
 - Continuation

Rituximab (MabThera®)

- **Rheumatoid Arthritis**
 - Continuation ONLY

Rituximab (Truxima®)

- **Rheumatoid Arthritis**
 - Initiation
 - Continuation

Secukinumab (Cosentyx®)

- **Ankylosing Spondylitis**
 - Initiation
 - Continuation
- **Psoriatic Arthritis**
 - Initiation
 - Continuation
- **Psoriasis**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 14 of 16	

Teriparatide (Forsteo®)

Osteoporotic fragility fractures in post menopausal women (secondary prevention)

- Initiation ONLY (max 24 month treatment)

Tocilizumab (RoActemra®)

- **Rheumatoid Arthritis**
 - Initiation
 - Continuation

Ustekinumab (Stelara®)

- **Psoriatic Arthritis**
 - Initiation
 - Continuation
- **Psoriasis**
 - Initiation
 - Continuation

Vedolizumab (Entyvio®)

- **Crohn's Disease**
 - Initiation
 - Continuation
- **Ulcerative Colitis**
 - Initiation
 - Continuation

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 15 of 16	

A		M	
Abatacept	10	MabThera®	14
Adalimumab	10	N	
Aflibercept	10	Non-radiographic Axial Spondyloarthritis	8
Ankylosing Spondylitis	7	O	
Apremilast	11	Orencia®	10
Avastin®	11	Osteoporotic fragility fractures	8
B		Otezla®	11
Benepali®	12	Ozurdex®	11
Bevacizumab	11	P	
Branch Retinal Vein Occlusion	6	Psoriasis	5
C		Psoriatic Arthritis	8
Certolizumab	11	R	
Cimzia®	11	Ranibizumab	14
Cosentyx®	14	Remicade®	13
Crohn's Disease	5	Remsima®	13
D		Rheumatoid Arthritis	9
Dexamethasone Intravitreal Implant	11	Rituximab	14
Diabetic Macular Oedema	6, 7	RoActemra®	15
E		S	
Enbrel®	12	Secukinumab	14
Entyvio®	15	Simponi®	12
Etanercept	12	Stelara®	15
Eylea®	10	T	
F		Teriparatide	15
Fluocinolone acetonide	12	Tocilizumab	15
Forsteo®	15	Truxima®	14
G		U	
Golimumab	12	Ulcerative Colitis	6
H		Ustekinumab	15
Humira®	10	V	
I		Vedolizumab	15
Iluvien®	12	W	
Inflectra®	13	Wet Age-related Macular Degeneration	7
Infliximab	13		
L			
Lucentis®	14		

Author	David Pollock	Date of Production	May 2017
Job Title	Clinical Integration Pharmacist	Review date	April 2018
Version	1.0	Page 16 of 16	